These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31339372)

  • 1. Recent advances in computational design of potent aromatase inhibitors: open-eye on endocrine-resistant breast cancers.
    Spinello A; Ritacco I; Magistrato A
    Expert Opin Drug Discov; 2019 Oct; 14(10):1065-1076. PubMed ID: 31339372
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
    Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer.
    Patani N; Martin LA
    Mol Cell Endocrinol; 2014 Jan; 382(1):683-694. PubMed ID: 24121024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.
    Spinello A; Martini S; Berti F; Pennati M; Pavlin M; Sgrignani J; Grazioso G; Colombo G; Zaffaroni N; Magistrato A
    Eur J Med Chem; 2019 Apr; 168():253-262. PubMed ID: 30822713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
    Caciolla J; Martini S; Spinello A; Pavlin M; Turrini E; Simonelli F; Belluti F; Rampa A; Bisi A; Fimognari C; Zaffaroni N; Gobbi S; Magistrato A
    Eur J Med Chem; 2021 Nov; 224():113733. PubMed ID: 34364162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational methods for the design of potent aromatase inhibitors.
    Favia AD; Nicolotti O; Stefanachi A; Leonetti F; Carotti A
    Expert Opin Drug Discov; 2013 Apr; 8(4):395-409. PubMed ID: 23373669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.
    Colozza M; Califano R; Minenza E; Dinh P; Azambuja E
    Mini Rev Med Chem; 2008 Jun; 8(6):564-74. PubMed ID: 18537711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
    Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
    Howell A; Dowsett M
    Breast Cancer Res; 2004; 6(6):269-74. PubMed ID: 15535858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the mechanisms of aromatase inhibitor resistance.
    Miller WR; Larionov AA
    Breast Cancer Res; 2012 Jan; 14(1):201. PubMed ID: 22277572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
    Macedo LF; Sabnis G; Brodie A
    Cancer; 2008 Feb; 112(3 Suppl):679-688. PubMed ID: 18072255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment.
    Gobbi S; Martini S; Rozza R; Spinello A; Caciolla J; Rampa A; Belluti F; Zaffaroni N; Magistrato A; Bisi A
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to aromatase inhibitors: where we stand!
    Augusto TV; Correia-da-Silva G; Rodrigues CMP; Teixeira N; Amaral C
    Endocr Relat Cancer; 2018 May; 25(5):R283-R301. PubMed ID: 29530940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.